Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL
Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia. A Multicenter, Open-label, Phase II Trial
Sponsor: Swiss Cancer Institute
Terminated
The board decision has been made to conclude the trial ahead of schedule. The primary endpoint has been successfully achieved and published, and funding was secured to support these three years of followup.
Other terminated trials from Swiss Cancer Institute
Other Chronic Lymphocytic Leukemia trials with similar outcome
This PHASE2 trial investigates Chronic Lymphocytic Leukemia and Leukemia and is currently terminated or withdrawn. Swiss Cancer Institute leads this study, which shows 20 recorded versions since 2019 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
20 versions recorded-
Jan 2026 — Present [monthly]
Terminated PHASE2
Status: Active Not Recruiting → Terminated
-
Sep 2025 — Jan 2026 [monthly]
Active Not Recruiting PHASE2
-
Aug 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE2
-
May 2025 — Aug 2025 [monthly]
Active Not Recruiting PHASE2
-
Sep 2024 — May 2025 [monthly]
Active Not Recruiting PHASE2
▶ Show 15 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
May 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
-
May 2023 — May 2024 [monthly]
Active Not Recruiting PHASE2
-
Apr 2022 — May 2023 [monthly]
Active Not Recruiting PHASE2
-
Dec 2021 — Apr 2022 [monthly]
Active Not Recruiting PHASE2
-
Oct 2021 — Dec 2021 [monthly]
Active Not Recruiting PHASE2
-
Jun 2021 — Oct 2021 [monthly]
Active Not Recruiting PHASE2
-
Jan 2021 — Jun 2021 [monthly]
Active Not Recruiting PHASE2
-
Sep 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Apr 2020 — Sep 2020 [monthly]
Recruiting PHASE2
-
Mar 2020 — Apr 2020 [monthly]
Recruiting PHASE2
-
May 2019 — Mar 2020 [monthly]
Recruiting PHASE2
-
Apr 2019 — May 2019 [monthly]
Recruiting PHASE2
-
Mar 2019 — Apr 2019 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Nov 2018 — Mar 2019 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Swiss Cancer Institute
For direct contact, visit the study record on ClinicalTrials.gov .